Home › Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.
 

Keywords :   


Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.

2016-02-28 04:00:20| Biotech - Topix.net

's stock had its "buy" rating restated by Noble Financial in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports. They presently have a $8.00 target price on the biotechnology company's stock.

Tags: inc buy rating financial

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
22.11Spain fines budget airlines including Ryanair 179m
22.11Eastern North Pacific Tropical Weather Outlook
22.11Atlantic Tropical Weather Outlook
22.11Rush PANTS
22.11SBS
22.11/
22.11 YOU
22.11
More »